4 unknown. 4 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 4 |
| Phase 3 | 2 | Unknown 2 |
Follow EC regimen: new trials by email Literature Review of EC regimen trials Research Report on EC regimen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer Fluzoparib+Paclitaxel, Epirubicin+Cyclophosphamide - TNBC - Triple-Negative Breast Cancer | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 60 | 2023-04-08 | 2023-04-28 |
| This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients AL3810, carboplatin + etoposide, Placebo - Extensive-stage Small Cell Lung Cancer | Phase 2 / Phase 3 | Unknown | Haihe Biopharma Co., Ltd. | 313 | 2019-11-14 | 2020-02-05 |
| Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma Simmtecan, 5-FU and l-LV, Toripalimab, Etoposide, Cisplatin - Neuroendocrine Carcinoma of the Bladder | Phase 2 / Phase 3 | Unknown | Peking University | 336 | 2019-06-19 | 2019-06-20 |
| A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients Epirubicin+Cyclophosphamide, liposomal-doxorubicin+Cyclophosphamide - Breast Cancer | Phase 2 | Unknown | TTY Biopharm | 254 | 2010-06-01 | 2021-11-23 |
Breast Neoplasms (1) · Carcinoma, Neuroendocrine (1) · Small Cell Lung Carcinoma (1) · Triple Negative Breast Neoplasms (1)
Haihe Biopharma Co., Ltd. (1) · Peking University (1) · TTY Biopharm (1) · The First Affiliated Hospital with Nanjing Medical University (1)
China (3) · Taiwan (1)
Lin Shen (1) · Ming-Feng Hou, MD (1) · Xiaoan Liu, Professor (1)